These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 28214929)

  • 1. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.
    Kortylewski M; Moreira D
    Cancer Immunol Immunother; 2017 Aug; 66(8):979-988. PubMed ID: 28214929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers.
    Moreira D; Adamus T; Zhao X; Su YL; Zhang Z; White SV; Swiderski P; Lu X; DePinho RA; Pal SK; Kortylewski M
    Clin Cancer Res; 2018 Dec; 24(23):5948-5962. PubMed ID: 30337279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.
    Zhang Q; Hossain DM; Duttagupta P; Moreira D; Zhao X; Won H; Buettner R; Nechaev S; Majka M; Zhang B; Cai Q; Swiderski P; Kuo YH; Forman S; Marcucci G; Kortylewski M
    Blood; 2016 Mar; 127(13):1687-700. PubMed ID: 26796361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
    Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
    Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.
    Won H; Moreira D; Gao C; Duttagupta P; Zhao X; Manuel E; Diamond D; Yuan YC; Liu Z; Jones J; D'Apuzzo M; Pal S; Kortylewski M
    J Leukoc Biol; 2017 Aug; 102(2):423-436. PubMed ID: 28533357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.
    Zhao X; Zhang Z; Moreira D; Su YL; Won H; Adamus T; Dong Z; Liang Y; Yin HH; Swiderski P; Pillai RK; Kwak L; Forman S; Kortylewski M
    Mol Ther; 2018 Mar; 26(3):695-707. PubMed ID: 29433938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.
    Hossain DM; Dos Santos C; Zhang Q; Kozlowska A; Liu H; Gao C; Moreira D; Swiderski P; Jozwiak A; Kline J; Forman S; Bhatia R; Kuo YH; Kortylewski M
    Blood; 2014 Jan; 123(1):15-25. PubMed ID: 24169824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.
    Zhang Q; Hossain DM; Nechaev S; Kozlowska A; Zhang W; Liu Y; Kowolik CM; Swiderski P; Rossi JJ; Forman S; Pal S; Bhatia R; Raubitschek A; Yu H; Kortylewski M
    Blood; 2013 Feb; 121(8):1304-15. PubMed ID: 23287859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bi-functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiation of acute myeloid leukemia in mice.
    Wang D; Kaniowski D; Jacek K; Su YL; Yu C; Hall J; Li H; Feng M; Hui S; Kaminska B; DeFranciscis V; Esposito CL; DiRuscio A; Zhang B; Marcucci G; Kuo YH; Kortylewski M
    Mol Ther Nucleic Acids; 2024 Sep; 35(3):102268. PubMed ID: 39171140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer.
    Ko HJ; Kim YJ
    Arch Pharm Res; 2016 Nov; 39(11):1597-1608. PubMed ID: 27572156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy.
    Alcantara MB; Tang WS; Wang D; Kaniowski D; Kang E; Dizman N; Chehrazi-Raffle A; Meza L; Zengin Z; Hall J; Hsu J; Egelston C; Moreira D; Horsager A; Pal SK; Kortylewski M
    Front Immunol; 2023; 14():1274781. PubMed ID: 38259453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity.
    Su YL; Banerjee S; White SV; Kortylewski M
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29921770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functionalized bioengineered spider silk spheres improve nuclease resistance and activity of oligonucleotide therapeutics providing a strategy for cancer treatment.
    Kozlowska AK; Florczak A; Smialek M; Dondajewska E; Mackiewicz A; Kortylewski M; Dams-Kozlowska H
    Acta Biomater; 2017 Sep; 59():221-233. PubMed ID: 28694238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy.
    Kortylewski M; Kujawski M; Herrmann A; Yang C; Wang L; Liu Y; Salcedo R; Yu H
    Cancer Res; 2009 Mar; 69(6):2497-505. PubMed ID: 19258507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
    Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
    Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR9-Targeted SiRNA Delivery In Vivo.
    Hossain DM; Moreira D; Zhang Q; Nechaev S; Swiderski P; Kortylewski M
    Methods Mol Biol; 2016; 1364():183-96. PubMed ID: 26472451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide.
    Oweida AJ; Mueller AC; Piper M; Milner D; Van Court B; Bhatia S; Phan A; Bickett T; Jordan K; Proia T; Schulick R; Messersmith WA; Del Chiaro M; Clambey E; Gough MJ; Williams J; Hansen K; Goodman K; Karam SD
    Cancer Immunol Immunother; 2021 Apr; 70(4):989-1000. PubMed ID: 33097963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.
    Moreira D; Zhang Q; Hossain DM; Nechaev S; Li H; Kowolik CM; D'Apuzzo M; Forman S; Jones J; Pal SK; Kortylewski M
    Oncotarget; 2015 Jul; 6(19):17302-13. PubMed ID: 26046794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors.
    Hellsten R; Lilljebjörn L; Johansson M; Leandersson K; Bjartell A
    Prostate; 2019 Oct; 79(14):1611-1621. PubMed ID: 31348843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
    Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
    Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.